Introduction
Lung cancer is the most common cause of cancer death worldwide (Statistical Annex, 2000) . Less than 15% of patients with lung cancer today will survive their disease. Survival of patients with advanced disease has not improved significantly over the last three decades (Jemal et al., 2002) . Essentially, the only patients who achieve long-term survival are those with Stage 0 or Stage I disease. The 5-year survival for patients with Stage 0 disease is 490% (Cortese et al., 1983; Melamed et al., 1984) . Unfortunately, patients with Stage 0 disease constitute only a minority of the lung cancer population (Fry et al., 1996) ; less than 0.6% of patients with lung cancer are currently diagnosed at this stage because these small cancers are usually asymptomatic. Therefore, if we wish to see a significant decrease in lung cancer mortality over the next several decades, a strategy of early detection, localization and treatment needs to be considered in addition to primary prevention measures.
The effects on long-term outcome of early detection and resection of non-small cell lung cancer remain controversial since the early studies using standard sputum cytology and chest X-ray Fontana et al., 1984; Frost et al., 1984; Polak, 1986, Kubik et al., 1990; Melamed et al., 1984; Tockman, 1986) . Although no improvement in mortality was found, survival, tumour resectability, and stage distribution were improved. Questions of over-diagnosis, and study design continue to be debated. Conventional chest X-rays are inferior to CT scans in the detection of resectable lung cancers. In a screening setting, chest X-ray has been shown to fail to detect 77% of all cancers, including 79% of tumours 420 mm and 50% 420 mm (Kaneko et al., 1996; Sone et al., 2000) . However, several new, very promising technologies have been developed in the last decade for detection and localization of early lung cancer. The potential of these new technologies, such as sputum biomarkers, low dose spiral CT, autofluorescence bronchoscopy, optical coherent tomography and confocal microendoscopy are discussed below.
Issues in early detection and diagnosis
The resurgence of interest and development of new technologies in lung cancer screening in recent years requires the definition of early lung cancer to be reassessed in terms of its biology and behaviour. Lung cancer consists of several types including small cell (SCLC and non-small cell (NSCLC). They may arise from the major bronchi (central) or from the peripheral structures (bronchioles and alveoli) of the lung.
Squamous cell carcinoma and SCLC usually arise centrally, while adenocarcinoma and large cell carcinoma usually arise peripherally. Because examination of the sputum and bronchoscopy examine the central airways, while spiral CT mainly detects peripheral tumours, different approaches are required for the detection of tumours in different compartments of the lung.
What is early lung cancer?
In order to develop and evaluate new methods of early detection, it is important to define the target lesion. A test that can detect invasive cancer may not have the same performance in detecting in situ carcinoma. It is also important to understand the biological behaviour of the tumours. As discussed below, the biological behaviour of lung tumours varies. Over-diagnosis, that is, diagnosis of morphologically malignant, but biologically indolent lesions that would not progress to clinical cancer during a patient's life-time, is always a concern in any screening programme. Therefore, it is important to understand the carcinogenesis process and correlate histopathology with the molecular profile and biology to define what constitutes an important early cancer to detect and treat.
Carcinogenesis process of lung cancer -morphological changes
The carcinogenesis sequence for squamous cell carcinomas has been defined and the development of squamous carcinoma has been studied in animal models (Nasiell et al., 1987) and humans (Saccomanno, 1982; Saccomanno et al., 1974; Auerbach et al., 1961 Auerbach et al., , 1978 Risse et al., 1988; Frost et al., 1986; Nasiell, 1966; Band et al., 1986; Melamed and Zaman, 1982) . However, it is less well understood for other cell types. Serial sputum cytology examinations in uranium miners and in smokers showed that invasive lung cancer develops through a series of stages from mild, moderate and severe atypia, carcinoma in situ and then invasive cancer (Saccomanno, 1982; Frost et al., 1986) . The sequence of progressive morphological and molecular changes may be regarded as the sequential theory of cancer development. In humans, the presence of dysplastic cells in sputum cytology or dysplastic lesions in bronchial biopsy, and the severity of abnormality correlate with the risk of development of invasive lung cancer in prospective studies. This is similar to what is known from cancer progression models in animals. The proportion of individuals with mild, moderate or severe sputum cell atypia who will develop invasive lung cancer within 10 years was found to be 4, 10 and 40% respectively (Risse et al., 1988; Frost et al., 1986) . Serial bronchoscopy and biopsy in patients with bronchial dysplasia showed that approximately 25% of the dysplastic lesions progress to invasive cancer over a mean period of 36 months. The dysplastic lesions were found to persist in another 42% (Shibuya et al., 2001) . Over 50% of patients with carcinoma in situ were found to progress to invasive cancer within 30 months (Thiberville et al., 1997; Venmans et al., 2000; Bota et al., 2001) . These numbers are probably low, since small lesions might have been removed by the biopsy procedure.
Little is known about the development of other tumour types, although atypical adenomatous hyperplasia (AAH) is considered to be the pre-invasive lesion of adenocarcinoma (Miller, 1990; Kerr, 1997; Mori et al., 1993) . These lesions are usually less than 7 mm in diameter and are detectable on CT scan as small, 'ground-glass' densities (Miller, 1990; Vazquez and Flieder, 2000) . In resected lungs, the incidence of AAH was estimated to be 9 to 21% in patients with primary lung cancer and 4 to 10% in patients without lung cancer (Kerr, 1997) . Laboratory investigations demonstrate that AAH cells have the ultrastructural features of Clara cells or Type II pneumocytes (Mori et al., 1998) and that many of the molecular changes present in lung adenocarcinomas are present in these lesions. AAH cells exhibit active proliferation, aneuploidy, 3p and 9p deletions, K-ras codon 12 mutation, and disruption of cell cycle control, but p53 gene aberrations are rare and telomerase activation is absent (Kitamura et al., 1999) . These findings support the concept that AAH lesions are precursor lesions of peripheral adenocarcinoma. Several types of adenocarcinoma with significant differences in radiological features, lymph node metastasis, tumour doubling time and prognosis have been described (Aoki et al., 2000; Noguchi et al., 1995; Yang et al., 2001) . Tumours with a predominant ground glass CT appearance showed a growth pattern involving replacement of alveolar lining cells (lepidic growth), and a better prognosis. As tumours appeared more solid on CT, they were associated with central fibrosis, alveolar collapse, and eventually a solid mass (hilic growth), and a less favourable outcome. The theory is that there is progression from the earlier lepidic growth with ground glass appearance to more solid tumours.
For small cell carcinomas, no characteristic morphological precursor lesions have been described. Recent molecular studies demonstrate extensive damage in the normal or hyperplastic epithelium of small cell lung cancer patients, suggesting that these tumours may arise directly from such epithelium without undergoing recognizable or defined preneoplastic lesions ('parallel theory of development'; Wistuba et al., 2000a) .
Carcinogenesis process of lung cancer -genetic changes
Our knowledge of genetic changes in the multi-stage pathogenesis of lung cancer is heavily biased towards a study of the changes in the central airways (bronchial epithelium) as this is repeatedly accessible via endoscopic examination or from examination of exfoliated sputum cells. Some information is available that the putative precursor lesions of peripheral adenocarcinomas, atypical adenomatous hyperplasias, have molecular changes similar to those present in invasive cancers (Kitamura et al., 1999; Kurasono et al., 1998; Ritter, 1999 (Hirsch et al., 2001) . In general, mutations follow a sequence, with allelic losses at chromosomes 3p, 9p and 8p are relatively early, losses and inactivation of the RB and TP53 genes are intermediate and losses at 5q are late events (Wistuba et al., 1997a (Wistuba et al., , 1999 . The losses at 3p are progressive, and advanced lesions and tumors often have lost most of the arm or the entire arm, while early lesions have more focal lesions (Wistuba et al., 2000b Current methods for mapping alterations, including loss of heterozygosity, comparative genomic hybridization and fluorescence in situ hybridization (FISH), are limited by inaccurately mapped, and insufficient numbers of markers and probes. Mapping using currently available markers leads to the identification of chromosomal regions too large for definition of candidate genes. Developing resources that can facilitate fine, genome-wide mapping of genetic alterations can aid the discovery of tumour suppressors and oncogenes by narrowing the area in which to search. Selection of overlapping BAC (bacterial artificial chromosome) clones based on the physical map of the human genome that span the lengths of chromosomes allows fine mapping at 0.1 to 0.2 Mb resolution. The feasibility of such an approach has recently reported for studying changes in chromosome 1p which is commonly altered in lung cancer (Henderson et al., 2002) .
Recently, gene expression profiles of lung cancer have been investigated using serial analysis of gene expression (SAGE) or cDNA microarray (Hibi et al., 1998; Nacht et al., 2001; Garber et al., 2001; Bhattacharjee et al., 2001; Giordano et al., 2001) . These studies were done in resected invasive tumours. Different gene expression profiles were found among squamous, large cell and small cell carcinoma as well as adenocarcinoma. Of importance is that the tumours can be sub-classified into groups that correlate with patient survival (Garber et al., 2001; Bhattacharjee et al., 2001) . Further studies are required to determine the extent to which differences in survival in patients with early stage (Stage I) lung cancer is due to limitation of the staging procedure rather than the molecular profiles of the tumours. PET imaging and radical lymph node dissection were not done for staging in the published reports (Garber et al., 2001; Bhattacharjee et al., 2001) . The potential limitations of these studies in invasive tumours may be overcome by studying preinvasive tumours. The small size of pre-invasive tumours has been a major barrier. The micro-SAGE technique was recently found to be applicable even to small, bronchoscopic biopsies from areas with carcinoma in situ localized by autofluorescence bronchoscopy (Lonergan et al., 2002) . This approach will likely lead to discovery of pathways key to the development of pre-invasive cancer.
Nodal involvement in sub-centimetre tumours
A number of authors have published data on nodal status of resected non-small cell lung cancers and have found that the incidence of regional lymph node involvement is related to size of the tumour. The incidence of N1/N2 nodal disease is approximately 8% for tumours 410 mm. For tumours over 3 cm, the incidence is approximately 38% (Oda et al., 1998; Henschke et al., 1999 Henschke et al., , 2001 Yoshida et al., 1998; Miller D, see http://www.webtie.org/SOTS/Meetings/ Lung/June%2019%202001/lectures.htm) (Tables 1 and  2 ). This gives encouragement to the argument that detection and treatment of smaller lesions may have a positive effect on outcome. However, this has been disputed by Patz et al. (2000) who did not find any correlation of tumour size with survival. However, the latter study included patients with Stage 1A (T1N0M0) cancers only and not all patients with tumours 43 cm. Furthermore, only 5% of the cancers evaluated (26/510 cases) were 510 mm.
Tumour growth rate
Lung cancers have a wide variation in growth characteristics, related to both cell type and individual Swensen et al. (2002) have shown that 18% of cancers detected at annual repeat CT screening were invisible on the previous scans taken a year earlier.
Both of these tumours were endobronchial in origin. Presumably, these tumours grew from a size that was below the resolution of the CT scan (1 -2 mm) to a readily detectable size in the interval. In the previous NCI chest X-ray screening studies, it was also observed that even with 4-monthly chest radiograph, 20% of the lung cancers were not visible in the prior examination (Muhm et al., 1983; Heelan et al., 1984) . Thus, some lung cancers are rapidly growing, thereby escaping early detection and leading to the occurrence of symptomatic interval cancers in a screening programme. If a significant proportion of tumours present as interval cases, the effectiveness of screening will be diminished. Tumour volume doubling time (VDT) in lung cancer is known to be an independent prognostic factor (Usuda et al., 1994) . Evaluation of VDT (Henschke et al., 2001; Sone et al., 2001 ) has shown wide variation between different cell types with the shortest times seen, as expected, in small cell lung cancers and the longest in adenocarcinoma (Table 3) . VDT of tumours in smokers is significantly shorter than in non-smokers . Some adenocarcinomas have VDT of 42 years, which sheds some concern on the standard 2 year follow-up protocol that is widely accepted in the medical community. Tumours with long VDT may be an important cause of overdiagnosis. For example, when a tumour grows from 3 to 15 mm in diameter, the tumour volume doubles approximately seven times. If the VDT were 365 days, it would take 7 years to grow from 3 to 15 mm, a size that has a significant metastatic potential. Detection of such slow growing tumors in the elderly or those with short life expectancy would not reduce lung cancer mortality.
Tumour biology
With the advent of in vivo functional imaging, it is now possible to evaluate the biological behaviour of tumours. Fluoride-18 fluorodeoxyglucose (FDG), used in positron emission tomography (PET), is taken up by metabolically active tumour cells. High glucose metabolism is associated with faster tumour growth. Duhaylongsod et al. (1995) reported that FDG uptake is correlated with the doubling time of malignant pulmonary lesions. Ahuja et al. (1998) reported that the SUR (standardized uptake ratio) in the PET image of the primary lesion correlated with prognosis. Bronchoalveolar carcinoma, known to have a long tumour doubling time and a better prognosis, is one of the causes of false negative PET scans because of the generally lower FDG uptake.
Further research is required to define what is early lung cancer in the context of early detection and treatment based on the biological, molecular and phenotypic profiles.
Test performance
The sensitivity, specificity, positive (PPV) and negative (NPV) predictive values are the usual parameters used for the evaluation of the performance of diagnostic techniques for lesion detection. It is important for a screening test for lung cancer to have a low false negative rate (i.e. good sensitivity), as lung cancer is known to have a poor prognosis. However, in screening, it is more important to have a test that has high specificity. A test with a high false positive rate and therefore a low positive predictive value will lead to unnecessary diagnostic tests and treatment with associated morbidity and even mortality. In addition, greater costs will be incurred without corresponding benefits to the patient or to society. Positive predictive value is influenced by disease prevalence in the screened population. For lung cancer, even among heavy smokers, the disease prevalence is generally 1% or less. For a screening test that has a specificity of less than 90%, the positive predictive value would be less than 10%.
Screening tools

Low dose spiral CT scan
The use of spiral CT scan in lung cancer screening studies has now been reported by a number of groups (Henschke et al., , 2001 Swensen et al., 2002; Sone et al., 2001; McWilliams et al., 2001b) . The majority of lung cancers found are Stage 1, with a mean diameter of 520 mm. It is clear that low dose spiral CT scans detect lung cancer at a smaller size and earlier stage than conventional chest X-ray.
However, the use of spiral CT scan alone as a screening tool has a number of limitations. This technique has high sensitivity for detection of noncalcified pulmonary nodules with lower specificity resulting in a large number of false positive tests, a low positive predictive value and a requirement for follow-up in a significant proportion of patients screened. The frequency of non-calcified pulmonary nodules/lesions found in a screened high-risk population varies from 23 -51% Swensen et al., 2002; McWilliams et al., 2001b) , with the majority of nodules measuring 510 mm in size. The positive predictive value of spiral CT is 12% or less (Table 4 ). In addition, CT scan is not sensitive for detection of superficial, pre-invasive/micro-invasive cancers in the central airways. If CT scans alone is Innovative approaches for detection of lung cancer A McWilliams et al used as a screening tool these treatable lesions will be missed. CT-detected small lung nodules pose a management problem. PET scan has been shown to be useful for both the assessment of pulmonary nodules 47 -8 mm, and staging of lung cancer (Lowe et al., 1998; Bury et al., 1997; Pieterman et al., 2000; Macmanus et al., 2001; Gupta et al., 1996 Gupta et al., , 2001 . A small study by Herder et al. (2001) showed that PET imaging might be useful in radiographically occult lung cancer in the central airways. However, PET is generally not useful in smaller lesions due to limitation in resolution and respiratory motion. Contrast CT scan, another current tool available for second line investigation of pulmonary nodules, has not been evaluated extensively in lesions of this size. Swensen et al. (2002) reports a sensitivity of 98% and specificity of 58% for contrast CT prediction of malignancy in pulmonary nodules. However, although some smaller nodules were included in the study, the mean diameter of malignant nodules was 16.9 mm. Fine-needle aspiration of nodules 510 mm is difficult for the majority of radiologists. At present, there are no non-invasive or minimally invasive techniques to differentiate a benign versus a malignant nodule smaller than 7 -8 mm. Development and validation of new technologies for investigation of small pulmonary lesions are urgently required. A new computer-aided method of growth assessment is being developed using three-dimensional reconstruction images . Using high resolution CT scans with 1 mm collimation, change in volume can be detected as early as 30 days for nodules that are 45 mm on initial presentation with a VDT 30 -180 days. This CT volumetric analysis is the beginning of new understanding of different growth characteristics of early lung cancers, and correlation with pathology and molecular biology will be invaluable.
Sputum biomarkers
Conventional cytology Sputum cytology examination is currently the only non-invasive method that can detect early lung cancer and pre-malignant lesions. Unfortunately, enthusiasm to use sputum cytology has been dampened by the negative screening studies in the 1970's. Although the specificity of conventional sputum cytology is very high (*98%), the sensitivity is very low.
In screening studies, the sensitivity is usually less than 20%. Tumour cell type, location and size affect the sensitivity of sputum cytology. The yield is highest in those with squamous cell carcinoma and lowest in adenocarcinoma (Koss et al., 1964; Risse et al., 1987; Rosa et al., 1973) . Tumours that are located centrally or in a lower lobe and are greater than 2 cm in diameter have a higher yield (Ng and Horak, 1983; Rosa et al., 1973; Umiker et al., 1957) . For example, in a screening setting in subjects with predominantly small peripheral cancers detected by spiral CT, only 11% of the lung cancers were detected by sputum cytology examination alone with another 15% detected by both methods (Kaneko et al., 1996 (Kaneko et al., , 1997 .
Newer detection methods using sputum cells To improve the sensitivity of sputum test as a screening tool for the detection of early lung cancer, three approaches are currently under development: immunostaining of transformed epithelial cells, PCR-based assays to detect oncogene mutations or and computerassisted image analysis of exfoliated sputum cells.
A nuclear ribonucleoprotein, hnRNP A2/B1, was found to be over-expressed in most lung cancer cell types as well as transformed epithelial cells (Zhou et al., 1996; . In a retrospective study using sputum specimens collected during the Johns Hopkins Lung Project, 64% of the subjects who showed moderate atypia and positive immunostaining for hnRNP A2/B1 developed lung cancer on follow-up, while 88% of those with negative immunostaining did not (Tockman et al., 1988) . The sensitivity increased to 91% if the specimens were limited to those that preceded the clinical appearance of lung cancer by less than 2 years. Two prospective studies evaluated hnRNP A2/B1 over-expression for the detection of pre-clinical lung cancer . At the end of the first year of follow-up, the positive predictive value of hnRNP over-expression in sputum cells was 67%. The sensitivity and specificity for predicting the development of second primary lung cancer was 77 and 82% respectively. For the development of primary lung cancer, the corresponding Figures were 82 and 65% respectively among the tin miners. Although the sensitivity is good, the specificity is too low to be useful as a screening tool.
PCR-based assays can detect one mutant-containing cell among an excess of 100 000 normal cells (Sidransky et al., , 1992 . Results reported from small retrospective studies (Mao et al., 1994; Yakubovskaya et al., 1995) have shown that K-ras and p53 mutations can be detected in sputum cells from some patients. However, mutations could also be seen in some control subjects. Because a given mutation is found in only a proportion of the patients with lung cancer and these genomic alterations may also be present in a number of smokers without lung cancer (Mao et al., 1997; Wistuba et al., 1997b) , the use of PCR-based assays needs to be evaluated in a prospective manner in a large population of smokers with and without lung cancer. There are as yet no long-term follow-up studies to determine the risk of lung cancer if one or more of these mutations were found. Furthermore, for genomic alterations such as p53, a variety of mutations have been found in lung cancer (Hollstein et al., 1991) . Multiple markers would be required to identify most of the common mutations if p53 were used for early detection.
Recently, Lacroix et al. (2001) has reported the use of reverse transcription PCR assays for preprogastrinreleasing peptide (preproGRP) to detect rare exfoliated tumour cells in peripheral venous blood and sputum samples in patients with lung cancer. These target transcripts are tightly suppressed in normal nonneoplastic tissues. Although the reported sensitivity and specificity was encouraging (30 and 100% respectively), the number of patients with early lung cancer was small. As well, the control group had very few highrisk subjects without lung cancer. Further studies are needed to validate the usefulness of this test.
There are as yet no long-term follow-up studies to determine the risk of lung cancer if one or more of these mutations were found. Furthermore, for genomic alterations such as p53, a variety of mutations have been found in lung cancer (Hollstein et al., 1991) . Multiple markers would be required to identify most of the common mutations if p53 were used for early detection.
Aberrant promoter methylation Cancers are accompanied by activation of oncogenes (such as Ras), and inactivation of multiple tumour suppressor genes (TSGs). Inactivation of TSGs requires loss of both alleles of the genes. Some TSGs, such as P53, are usually inactivated by a combination of point mutations and allelic loss. However, aberrant methylation of the promoter regions of many genes is emerging as the major mechanism of gene silencing in human cancers . Frequently a combination of methylation of one allele accompanied by allelic loss of the other is present. Each major form of cancer has its specific methylation profile. A number of groups have described the profiles of the major forms of lung cancer Toyooka et al., 2001; ZochbauerMuller et al., 2001) . Methylation commences early during the pathogenesis of lung cancer (Belinsky et al., 1998) , and detection of methylated sequences in the sputum of heavy smokers may predict those at greatest risk of developing cancer (Palmisano et al., 2000) .
Molecular examination of a variety of specimens may aid the early diagnosis of both central and peripheral lung cancers. These include sputum and bronchial brushes (for central tumours), bronchioloalveolar lavage fluids (for peripheral tumours) and the buccal mucosa (as a surrogate organ) (Ahrendt et al., 1999; Soria et al., 2002) .
Immunostaining and PCR-based methods require the presence of pre-malignant or malignant cells for diagnosis. Pre-invasive cancers, especially peripheral adenocarcinomas, typically do not exfoliate many cells into the bronchial lumen. The adequacy of the specimen is influenced by the subject's performance and collection method. For example, a study by the Lung Cancer Early Detection Working Group showed that with sputum induction using hypertonic saline, 19.6% of the specimens from current smokers and 28.9% of the specimens from former smokers were unsatisfactory .
Computer-assisted image analysis of sputum cells
The use of non-genetic changes in normal cells that are induced by the presence of malignant cells in the vicinity such as malignancy associated changes (MACs) (Nieburgs et al., 1959) may overcome the problems discussed above. MACs refer to sub-visual or nonobvious changes in the distribution of DNA in the nuclei of normal cells due to the presence of preinvasive or invasive cancer in the vicinity. These changes can be quantitated by computer-assisted image analysis (Palcic and MacAulay, 1994) . In a study using bronchial biopsies taken from the opposite lung or from a lobe different from the primary tumour, MACs was found to be present in 86% of the normal appearing specimen (MacAulay et al., 1995) . Even more interesting is the finding in a retrospective analysis of sputum cytology slides that were collected during the Mayo Lung Project (Payne et al., 1997) . MACs alone correctly identified 74% of the subjects who later developed lung cancer. Furthermore, the presence of MACs was found to precede clinical diagnosis by 12 months or more. A previous assessment of this quantitative and qualitative DNA technique gave sensitivity of 75% and specificity of 90% for Stage 0 and I lung cancers .
The advantage of this approach is that the method is not dependent on the presence of malignant cells in the sputum although the presence of atypical or malignant cells can improve the sensitivity of detection to over 90% (Payne et al., 1997) .
Research being performed with this technique at the British Columbia Cancer Agency proposes that computer-assisted image analysis of sputum cells may be a first step screening test for early detection of lung cancer. Sputum induction with hypertonic saline and high frequency chest wall oscillation vest (ABI, Inc.) results in good yields of lower respiratory tract cells with only a 1% inadequate sample rate. Preliminary data from an ongoing study using combined sputum analysis and low dose spiral CT scan for lung cancer screening (McWilliams et al., 2001b) has revealed that all cases of lung cancer found on CT screening had abnormal cells by image cytometry. No lung cancer has yet been diagnosed in subjects with normal sputum analysis. In addition, two CT-occult cancers were diagnosed in the abnormal sputum group via autofluorescence bronchoscopy.
Molecular detection of genetic changes in the blood
Several investigators are exploring detection of circulating tumour cells many using innovative means of cell capture and analysis of epithelial cell or tumour cell specific markers. Molecular changes characteristic of specific tumours may be detected in the plasma or serum. These changes include gene mutations (Ras, P53) and abnormally methylated genes (Brabender et al., 2001; Esteller et al., 1999) . The use of blood based screening tests requires further investigation.
Effects of smoking cessation After smoking cessation, the risk of developing lung cancer falls, but never reaches the baseline levels of never smokers (Peto et al., 2000) . After smoking cessation, metaplastic and mild dysplastic changes frequently regress, while moderate
Innovative approaches for detection of lung cancer
A McWilliams et al to severe dysplastic changes persist (Lam et al., 1999) and these changes have been utilized as surrogate end points for chemoprevention studies. Our recent, unpublished data indicates that methylation changes (which are potentially reversible epigenetic changes) may diminish after smoking cessation but remain elevated compared to baseline levels. Thus, smoking cessation is accompanied by partial but not complete regression of morphological and molecular changes. These persistent changes may be the reason for the increased lifetime risk of lung cancer in former smokers.
Localization techniques Because of the complex anatomy of the respiratory tract, a screening test must be able to assess both peripheral and central airway structures. CT scan, although very sensitive for detection of small peripheral nodules, is not adequate for assessment of the endobronchial tree. Abnormal sputum biomarkers can indicate the presence of precancerous or cancerous lesions in the respiratory tract but cannot localize the source of the abnormal cells.
Autofluorescence bronchoscopy
Localization of pre-invasive and early invasive lung cancer is difficult with white light bronchoscopy as less than 40% of carcinoma in situ is detectable (Woolner, 1983; Lam et al., 2000a) . This clinical problem, combined with the improvement of medical endoscopes, light sources, optical fibres, and imaging and non-imaging detectors, have driven the development of autofluorescence bronchoscopy for the localization of early, pre-invasive lung cancer. This technique utilizes the difference in autofluorescence spectra between normal bronchial tissue and pre-malignant/malignant tissue. There has been recent interest and effort by a number of companies in design, construction and clinical trials of endoscopic autofluorescence imaging devices for localization of pre-invasive and early invasive bronchial cancers. (Examples of this include: Xillix Technologies, Vancouver, Canada; Pentax, Japan; Karl Storz GmbH, Tuttlingen, Germany and Richard Wolf GmbH, Knittlingen, Germany.) Of all the commercial systems, the Xillix (LIFE) is the oldest and the only one that has received world-wide regulatory approval for clinical use. Most of the published clinical studies are with this device. The approved clinical device uses a He-Cd laser (442 nm) to excite the autofluorescence of the bronchial tissue. Normal tissue fluoresces green while precancerous or cancerous tissues fluoresce brown or brownish red. A second clinical prototype uses a filtered Xe lamp (blue light excitation). It has been investigated world-wide in over 1600 patients and is now a well established technique with twice the sensitivity of white light bronchoscopy in detection of these lesions on the average (sensitivity 80% vs 40%) (Lam et al., 2000a; Wagnieres et al., 2002) . An example of a carcinoma in situ lesion localized by autofluorescence bronchoscopy in a high-risk smoker with atypical cells in the sputum is illustrated in Figure 1 . False-positive biopsies are usually due to inflammation and severe goblet cell hyperplasia. One technique that is being investigated to improve specificity and reduce observer variation in interpretation is the use of quantitative measurement in real-time during the procedure. This has been shown to improve the specificity for the detection of high-grade lesions (McWilliams et al., 2001a) . The current limitation in applying this method to central airway cancers is related to the size of the fibreoptic bronchoscope. Small fibreoptic instruments less than 1 mm in diameter is now available for endoscopic examination of mammary ducts of the breast. In conjunction with 3-D reconstruction of spiral CT b a Figure 1 White-light (a) and autofluorescence (b) bronchoscopy images of a carcinoma in situ lesion in the left upper lobe of a high-risk smoker with atypical cells on image cytometry. The lesion is indicated by an arrow. There was slight thickening of the bronchial mucosa on white light bronchoscopy. The lesion is clearly seen as a brownish area under autofluorescence bronchoscopy
Innovative approaches for detection of lung cancer A McWilliams et al images, it may be possible to apply spectral (fluorescence and reflectance) bronchoscopy with these microinstruments to diagnose and treat small peripheral lesions detected by spiral CT.
Virtual bronchoscopy
Virtual bronchoscopy uses perspective surface or volume rendering generated from CT data to produce endoscopic-like visualizations of the airways. Current efforts can visualize to about the sixth branch level or down to a diameter of 1.2 mm (Mori et al., 2000) . Semi-automated and automated construction of a virtual map of the central airways can be readily done (Sonka et al., 1994; Summers et al., 1998) . Newer high resolution spiral CT systems will enable even finer virtual mapping of the bronchus (Dawn et al., 2001; Haponik et al., 1999) . This technology also allows the detection and localization of small benign and malignant nodules in the lung periphery (Dawn et al., 2001; Seemann and Claussen, 2001; Aquino and Vining, 1999) . Combining these methodologies could enable the mapping of the bronchial passages and branching pattern from the central airways to the lung nodules in the periphery, or close (52 mm) to these nodules.
Concurrently there are many groups developing optically based, small fibreoptic probes which can non-invasively visualize tissue structure; at the level of individual cells (*1 to 2 mm) from the tissue surface down to *150 mm deep into the tissue (fibreoptic confocal microscopy), or at the level of changes in collections of cells in tissue layers or tissue structures (*2 to 10 mm) from the bronchial surface down to *2 mm deep into the bronchial wall (Optical Computed Tomography, OCT). The small probe sizes and the flexibility of these new tissue visualizing optical probes may allow them to reach the periphery of the lung through the bronchial passages given adequate details from a virtual bronchoscopy map.
Optical coherent tomography
Optical Computed Tomography (OCT) uses temporally incoherent light that is split; one part directed down a sample probe to interact with the tissue and return and another part that is directed down a reference arm and returned from a reference mirror. The returning light from the two paths is recombined and interferes constructively and destructively with each other. When the distance the light travels down the reference arm exactly matches the distance the light travels down the probe arm and reflects off a structure in the tissue being imaged, constructive interference occurs, and a signal is detected. The distance the light travels along the reference arm can be rapidly and precisely controlled (at KHz rates) enabling the rapid scanning of reflective signals with in the tissue at the end of the probe arm (Rollins et al., 1998; Huang et al., 1991; Rollins and Izatt, 1999 ; J Fujimoto, see http://optics.org/article/ole/ feature/1/88/2?year=20oldmonth=10 (cited 30 January 2002)). The resultant signal appears similar to an ultrasound signal. In a similar fashion, if the light beam into the tissue is scanned in a radial or transverse fashion, an image can be formed exactly like ultrasound imaging but with a much higher resolution (10 to 2 mm). The development of small (2 to 50.5 mm) OCT probes for the GI tract and cardiovascular system enables acquisition of high resolution (10 to 2 mm) 2D images of tissue structures in vivo from areas traditionally impossible to image non-invasively Huang et al., 1991) . The structures commonly seen by such systems are the boundaries between different tissue layers such as the epithelium and the basement membrane (Izatt et al., 1996) .
Confocal microscopy
Extending on the work done for in vivo imaging in the dermis using confocal microscopy (Rajadhyaksha et al., 1995) , confocal microendoscopy or fibreoptic confocal microscopy uses a modified high speed epiillumination confocal microscope in which the conventional objective lens system has been replaced by a combination of lenses and fibreoptics. These research systems can currently image up to 150 mm into tissue (Smithpeter et al., 1998) with a spatial resolution between 1 to 2 mm through flexible fibreoptic imaging systems 7 to 1.8 mm in diameter (Gmitro and Aziz, 1993; Sabharwal et al., 1999; Lane et al., 2000 Lane et al., , 2001 . Using the native optical properties of the tissue (differences in back scattering intensity between the cytoplasm and nuclei or tissue autofluorescence), these systems allow the imaging of individual cell nuclei without staining. In general, all the current systems use a confocal microscope spot or slit scanning type system in which the conventional object lens has been replaced by a proximal lens system which couples the scanning spot or slit of the confocal system into a coherent fibreoptic bundle. This fibre bundle transmits light to a distal lens system and then into the tissue. The reflected light or fluorescence light generated by the tissue in vivo is then focused back into the fibre bundle by the distal lens system, transmitted back up the fibre bundle where the proximal lens system in conjunction with the rest of the confocal microscope separates the light generated in the optical sample focal plane from the out of focus light. An alternative approach being developed is to use a single fibre to transmit the illumination light and receive the in focus return light from a distal spot scanning system constructed using micro machined optical mechanical mirrors and appropriate miniature optics (Dickensheets and Kino, 1996) . With the explosion in new optical imaging modalities and the steady improvement of existing non-invasive imaging modalities, the possibility of detecting and localizing early lung cancer has never looked more positive.
Concluding remarks
The failure of current technologies to impact on lung cancer survival has led to a host of innovative, newer 
